Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Nevirapine: pharmacokinetic considerations in children and pregnant women.

Mirochnick M, Clarke DF, Dorenbaum A.

Clin Pharmacokinet. 2000 Oct;39(4):281-93. Review.

PMID:
11069214
2.

Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Bardsley-Elliot A, Perry CM.

Paediatr Drugs. 2000 Sep-Oct;2(5):373-407. Review.

PMID:
11022799
3.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD003510. doi: 10.1002/14651858.CD003510.pub3. Review.

PMID:
21735394
4.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2011;(7):CD003510.

PMID:
17253490
5.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
6.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
7.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Brocklehurst P, Volmink J.

Cochrane Database Syst Rev. 2002;(2):CD003510. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD003510.

PMID:
12076484
8.

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Brocklehurst P, Volmink J.

Cochrane Database Syst Rev. 2002;(1):CD003510. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD003510.

PMID:
11869666
9.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
10.

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.

Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL.

J Infect Dis. 1998 Aug;178(2):368-74.

PMID:
9697716
11.

Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.

Suksomboon N, Poolsup N, Ket-Aim S.

J Clin Pharm Ther. 2007 Jun;32(3):293-311. Review.

PMID:
17489882
12.

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.

Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL.

Pediatr Infect Dis J. 2001 Aug;20(8):803-5.

PMID:
11734746
13.

Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Bhana N, Ormrod D, Perry CM, Figgitt DP.

Paediatr Drugs. 2002;4(8):515-53. Review.

PMID:
12126455
14.

Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.

Giaquinto C, Rampon O, De Rossi A.

Clin Drug Investig. 2006;26(11):611-27. Review.

PMID:
17163296
15.

Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.

Senise JF, Castelo A, Martínez M.

AIDS Rev. 2011 Oct-Dec;13(4):198-213. Review.

PMID:
21975356
16.

Nevirapine concentrations in newborns receiving an extended prophylactic regimen.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.

PMID:
18398973
17.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F; Ghent Group on HIV in Women and Children.

Int J Epidemiol. 2007 Oct;36(5):1009-21. Epub 2007 May 28. Review.

PMID:
17533166
18.

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH.

AIDS. 2000 Jul 28;14(11):F111-5.

PMID:
10983633
19.

A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.

Thistle P, Spitzer RF, Glazier RH, Pilon R, Arbess G, Simor A, Boyle E, Chitsike I, Chipato T, Gottesman M, Silverman M.

Clin Infect Dis. 2007 Jan 1;44(1):111-9. Epub 2006 Nov 22.

PMID:
17143826
20.

Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.

Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, Sakarovitch C, Becquet R, Fassinou P, Dequae-Merchadou L, Welffens-Ekra C, Rouzioux C, Leroy V; ANRS 1201/1202 DITRAME PLUS Study Group.

AIDS. 2005 Feb 18;19(3):309-18.

Supplemental Content

Support Center